S05.1 Efficacy and safety of the anti-SARS-CoV-2 BNT162b2 vaccine among SLE patients: the covalus project

S05.1 Efficacy and safety of the anti-SARS-CoV-2 BNT162b2 vaccine among SLE patients: the covalus project

Bibliographic Details
Main Authors:	V Ferré, T Papo, N Charles, A Mageau, P Nicaise Roland, T Goulenok, J Tchen, K Sacre
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-10-01
Series:	Lupus Science and Medicine

Similar Items

S05.2 Risk of COVID-19 induced systemic lupus erythematosus flare: analysis of the AP-HP clinical data warehouse
by: T Papo, et al.
Published: (2022-10-01)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
by: Geon Young Ko, et al.
Published: (2023-10-01)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
by: Rieke Reiter, et al.
Published: (2022-05-01)

Myopericarditis following both BNT162b2 and NVX-CoV2373
by: Saima Ahmad, et al.
Published: (2022-12-01)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
by: Tomer Hertz, et al.
Published: (2023-07-01)

Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients
by: Fabrizia Valleriani, et al.
Published: (2021-10-01)

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children
by: Yannic C. Bartsch, et al.
Published: (2022-12-01)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
by: Xin Rong Lim, et al.
Published: (2021-08-01)

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis
by: Wonngarm Kittanamongkolchai, et al.
Published: (2022-07-01)

Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
by: Mina Psichogiou, et al.
Published: (2021-09-01)

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
by: Nick K Jones, et al.
Published: (2021-04-01)

P051: Withdrawn
Published: (2024-01-01)

Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
by: Samuel M.S. Cheng, et al.
Published: (2024-03-01)

Longitudinal Analysis of Antiphospholipid Antibody Dynamics after Infection with SARS-CoV-2 or Vaccination with BNT162b2
by: Manca Ogrič, et al.
Published: (2022-12-01)

Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
by: Eleni Papadokostaki, et al.
Published: (2022-03-01)

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
by: Jing Zou, et al.
Published: (2021-03-01)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
by: Michael Jahn, et al.
Published: (2021-04-01)

Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population
by: Chloé Dimeglio, et al.
Published: (2023-06-01)

Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
by: Angelos Hatzakis, et al.
Published: (2022-02-01)

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
by: Aharona Glatman-Freedman, et al.
Published: (2022-05-01)

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
by: Catherine Riou, et al.
Published: (2024-01-01)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
by: Stilla Bauernfeind, et al.
Published: (2021-09-01)

Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
by: Rune M. Pedersen, et al.
Published: (2022-06-01)

PB2236: HUMORAL RESPONSE TO SARS-COV-2 VACCINATION WITH BNT162B2 COVID-19 MRNA IN PATIENTS WITH HAEMOGLOBINOPATHIES
by: I. Giatagantzidou, et al.
Published: (2022-06-01)

Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2
by: Paola Zelini, et al.
Published: (2022-08-01)

Effect of SARS-CoV-2 Infection and BNT162b2 Vaccination on the mRNA Expression of Genes Associated with Angiogenesis
by: Paulina Wigner-Jeziorska, et al.
Published: (2023-11-01)

SARS-CoV-2 Specific Humoral Immune Responses after BNT162b2 Vaccination in Hospital Healthcare Workers
by: Maryam Golshani, et al.
Published: (2022-11-01)

Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI
by: Raul Pellini, et al.
Published: (2021-06-01)

Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination
by: Vincenzo Puro, et al.
Published: (2021-06-01)

Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination
by: Dong-Ho Jo, et al.
Published: (2021-10-01)

BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients
by: Michal Herman-Edelstein, et al.
Published: (2022-06-01)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
by: Davide Ferrari, et al.
Published: (2021-11-01)

Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2
by: Marcello Salvaggio, et al.
Published: (2021-09-01)

Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals
by: Zoltán Szekanecz, et al.
Published: (2023-11-01)

Combined copper and zinc deficiency is associated with reduced SARS-CoV-2 immunization response to BNT162b2 vaccination
by: Thilo Samson Chillon, et al.
Published: (2023-10-01)

Longitudinal study of antibody response following SARS-CoV-2 vaccination with Pfizer-BioNTech BNT162b2
by: Robles Navas Leandra J., et al.
Published: (2023-08-01)

Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?
by: Avraham Ishay, et al.
Published: (2023-02-01)

Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations
by: Thomas Perkmann, et al.
Published: (2023-08-01)

Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes
by: Hamdi Cihan Emeksiz, et al.
Published: (2023-06-01)

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
by: Jaime S. Rosa Duque, et al.
Published: (2022-08-01)